University of Innsbruck
von links Michael Ahlijanian, Paulo Fontoura, Christoph Schwarzer, Georg Singewald, Clemens Decristoforo und Jörg Striessnig.

from left: Michael Ahlijanian (Pinteon Therapeutics and Orthogonal Neurosciences), Paulo Fontoura (Roche), Christoph Schwarzer (Medical University of Innsbruck), Georg Singewald (Roche), Clemens Decristoforo (University of Innsbruck) und Jörg Striessnig (University of Innsbruck).

Inter­na­tional experts intro­duce new mas­ter's degree in phar­macy

Since the winter semester 2022/23, the University of Innsbruck and the Medical University of Innsbruck offer the joint master's programme "Pharmaceutical Sciences". International experts from industry and regulatory authorities were guests at the kick-off.

Students interested in natural sciences have a new educational opportunity since this semester: The University of Innsbruck and the Medical University of Innsbruck have jointly launched the master's programme "Pharmaceutical Sciences - Drug Development and Regulatory Affairs".

The development and approval of next-generation drugs is at the center of the teaching content of the English-language degree programme. In addition to lecturers from both universities, experts from the pharmaceutical industry and regulatory authorities make a significant contribution to the attractiveness of the programme. More than 50 students and interested parties were present at the kick-off for the new programme, when high-ranking experts were guests at the University of Innsbruck:

Paulo Fontoura, Head of Translational Medicine for Neuroscience and Rare Diseases at Roche, spoke about translational medicine and clinical development of novel therapeutics in neuroscience. Michael Ahlijanian, chief scientific officer of Pinteon Therapeutics and Orthogonal Neurosciences, gave a talk on major challenges in drug development. Finally, Harald Enzmann, Chairman of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) provided attendees an insight into the complex process of marketing authorization of medicines.

Information about the Master "Pharmaceutical Sciences - Drug Development and Regulatory Affairs" can be found on the programme website. Registration for the Master will be open from March 1, 2023.